Insights

Expanding Nutraceuticals Ceapro's focus on developing oat beta glucan and avenanthramides for nutraceutical applications presents a strong opportunity to collaborate with health supplement and functional food companies seeking natural, evidence-based ingredients.

Cosmetic Industry Potential With its proprietary oat extracts known for skin hydration and anti-inflammatory benefits, Ceapro can target skincare brands interested in natural, science-backed active ingredients for anti-aging and Sensitive skin product lines.

Innovative Technology Edge Ceapro's unique PGX technology and plant extraction processes enable the production of high-value bio-nanocomposites and bioactive ingredients, offering a competitive advantage for partners looking for innovative, sustainable processing solutions.

Global Market Access Having existing well-known clients and health claims approved in major markets like North America and Europe indicates strong potential for expanding into international nutraceutical, cosmetic, and healthcare markets seeking proven natural ingredients.

Sustainability Focus Ceapro’s use of renewable plant resources and proprietary extraction methods aligns well with brands prioritizing sustainable and environmentally friendly sourcing, creating entry points with eco-conscious companies within health and beauty sectors.

Ceapro Tech Stack

Ceapro uses 8 technology products and services including Amazon Web Services, WordPress, Font Awesome, and more. Explore Ceapro's tech stack below.

  • Amazon Web Services
    Cloud Hosting
  • WordPress
    Content Management System
  • Font Awesome
    Font Scripts
  • Modernizr
    Javascript Libraries
  • Lightbox
    Javascript Libraries
  • jQuery
    Javascript Libraries
  • PHP
    Programming Languages
  • Apache HTTP Server
    Web Servers

Media & News

Ceapro's Email Address Formats

Ceapro uses at least 1 format(s):
Ceapro Email FormatsExamplePercentage
FLast@ceapro.comJDoe@ceapro.com
47%
First@ceapro.comJohn@ceapro.com
4%
First.Last@ceapro.comJohn.Doe@ceapro.com
2%
FLast@ceapro.comJDoe@ceapro.com
47%

Frequently Asked Questions

What is Ceapro's stock symbol?

Minus sign iconPlus sign icon
Ceapro is a publicly traded company; the company's stock symbol is CZO.V.

What is Ceapro's official website and social media links?

Minus sign iconPlus sign icon
Ceapro's official website is ceapro.com and has social profiles on LinkedInCrunchbase.

How much revenue does Ceapro generate?

Minus sign iconPlus sign icon
As of December 2025, Ceapro's annual revenue is estimated to be $5M.

What is Ceapro's SIC code NAICS code?

Minus sign iconPlus sign icon
Ceapro's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Ceapro have currently?

Minus sign iconPlus sign icon
As of December 2025, Ceapro has approximately 28 employees across 3 continents, including North AmericaSouth AmericaAfrica. Key team members include Ceo Y Fundador: R. V. U.Chief Revenue Officer: S. W.Chief Financial Officer: S. P.. Explore Ceapro's employee directory with LeadIQ.

What industry does Ceapro belong to?

Minus sign iconPlus sign icon
Ceapro operates in the Biotechnology Research industry.

What technology does Ceapro use?

Minus sign iconPlus sign icon
Ceapro's tech stack includes Amazon Web ServicesWordPressFont AwesomeModernizrLightboxjQueryPHPApache HTTP Server.

What is Ceapro's email format?

Minus sign iconPlus sign icon
Ceapro's email format typically follows the pattern of FLast@ceapro.com. Find more Ceapro email formats with LeadIQ.

How much funding has Ceapro raised to date?

Minus sign iconPlus sign icon
As of December 2025, Ceapro has raised $480K in funding. The last funding round occurred on Nov 29, 2021 for $480K.

Ceapro

Biotechnology ResearchAlberta, Canada11-50 Employees

Ceapro Inc. is a Canadian biotechnology company involved in the development and commercialization of “active ingredients” derived from oats and other renewable plant resources for healthcare and cosmetic industries. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions.

Ceapro’s patented process technologies include its Pressurized Gas eXpanded (PGX) technology which is a unique and disruptive technology with several key advantages over conventional drying and purification methods that can be used to process biopolymers into high-value, nano-sized polymer structures and novel bio-nanocomposites. Ceapro also utilizes its proprietary plant extraction-based manufacturing process to supply ingredients to well-known personal care and cosmetic industries worldwide.

The Company’s two value-driving products, oat beta glucan and avenanthramides, are found in many household names, cosmetic and personal care brands. These products are manufactured from Ceapro’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Oat beta glucan effectively stimulates collagen synthesis and deeply moisturizes the skin (epidermis and dermis) thereby improving skin restructuring, decreasing wrinkles and allowing wound healing with minimal scaring. When taken orally, oat beta glucan has been shown to improve cholesterol levels and therefore has “heart health” approved health claims in Canada, United States and Europe.  Avenanthramides are polyphenolic compounds found exclusively in oats which act as natural anti-oxidant, anti-irritant and anti-inflammatory. When added to topical formulation, avenanthramides effectively reduce redness and itchiness due to inflammation. In oral formulations, avenanthramides could treat serious conditions triggered by inflammation.  Given the therapeutic benefits of the Company’s two flagship products, Ceapro is currently expanding and developing them for use in the nutraceutical industries.

Section iconCompany Overview

Website
ceapro.com
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
CZO.V
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
11-50

Section iconMedia & News

Section iconFunding & Financials

  • $480K

    Ceapro has raised a total of $480K of funding over 4 rounds. Their latest funding round was raised on Nov 29, 2021 in the amount of $480K.

  • $100M$250M

    Ceapro's revenue is estimated to be in the range of $100M$250M

Section iconFunding & Financials

  • $480K

    Ceapro has raised a total of $480K of funding over 4 rounds. Their latest funding round was raised on Nov 29, 2021 in the amount of $480K.

  • $100M$250M

    Ceapro's revenue is estimated to be in the range of $100M$250M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.